0.5M Na Lactate Solution in Acute Heart Failure (AHF)
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial to see whether:
-Cardiac performance (cardiac index and secondary outcomes)can be improved in patients with
acute heart failure (AHF) and symptoms and consequences of fluid overload (pulmonary and
interstitial edema) and poor peripheral perfusion can be reduced by:
1. Providing lactate as a substrate(Improve cardiac index)
2. Simultaneously restoring optimal preload
Optimal standard treatment will be achieved in both arms with the use of current best
treatment protocol for AHF as per independent treating physician.
4. To assess effects of 0.5M Na lactate (Totilac) on plasma and urine biological parameters
(sodium, potassium, chloride, pH, bicarb, base excess, albumin)
5. To assess effects of 0.5M Na lactate on morbidity and mortality.